-
Mallinkcrodt Is Betting On Ocera Despite Doubts Around Its Liver Disease Drug
Thursday, November 2, 2017 - 2:43pm | 389Mallinckrodt PLC (NYSE: MNK), a generic specialty pharmaceutical company, said Thursday it has agreed to acquire Ocera Therapeutics Inc (NASDAQ: OCRX), a nano-cap clinical-stage biopharmaceutical company for $1.52 per share plus a contingent value right. Ocera's stock soared higher by 70...